Tianqi Xu

416 total citations
31 papers, 278 citations indexed

About

Tianqi Xu is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Tianqi Xu has authored 31 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Radiology, Nuclear Medicine and Imaging, 15 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Tianqi Xu's work include Monoclonal and Polyclonal Antibodies Research (26 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and HER2/EGFR in Cancer Research (12 papers). Tianqi Xu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (26 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and HER2/EGFR in Cancer Research (12 papers). Tianqi Xu collaborates with scholars based in Sweden, Russia and China. Tianqi Xu's co-authors include Vladimir Tolmachev, Anna Orlova, Anzhelika Vorobyeva, Maryam Oroujeni, Torbjörn Gräslund, Sara S. Rinne, Javad Garousi, Е. В. Коновалова, Alexey Schulga and Jie Zhang and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Controlled Release and Molecules.

In The Last Decade

Tianqi Xu

29 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tianqi Xu Sweden	12	222	117	104	31	18	31	278
Hanieh Khalili United Kingdom	8	162 0.7×	76 0.6×	173 1.7×	34 1.1×	11 0.6×	16	314
Sam Heywood United Kingdom	10	195 0.9×	60 0.5×	210 2.0×	49 1.6×	21 1.2×	18	318
Jacqueline Mock Switzerland	10	118 0.5×	226 1.9×	93 0.9×	84 2.7×	7 0.4×	19	306
Angela Mountain United Kingdom	8	177 0.8×	41 0.4×	149 1.4×	49 1.6×	17 0.9×	10	260
Tamara Hell Switzerland	4	203 0.9×	240 2.1×	156 1.5×	54 1.7×	18 1.0×	4	340
Philip W. Howard United Kingdom	8	112 0.5×	129 1.1×	83 0.8×	33 1.1×	5 0.3×	15	214
Michael F. Giblin United States	10	244 1.1×	129 1.1×	136 1.3×	21 0.7×	38 2.1×	14	355
Natalia Nuñez‐Prado Spain	10	209 0.9×	160 1.4×	164 1.6×	116 3.7×	3 0.2×	11	329
Anthony Manibusan United States	8	106 0.5×	98 0.8×	142 1.4×	19 0.6×	7 0.4×	10	241
Sébastien Calloud Switzerland	6	157 0.7×	69 0.6×	137 1.3×	137 4.4×	8 0.4×	8	289

Countries citing papers authored by Tianqi Xu

Since Specialization

Citations

This map shows the geographic impact of Tianqi Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tianqi Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tianqi Xu more than expected).

Fields of papers citing papers by Tianqi Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tianqi Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tianqi Xu. The network helps show where Tianqi Xu may publish in the future.

Co-authorship network of co-authors of Tianqi Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Tianqi Xu. A scholar is included among the top collaborators of Tianqi Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tianqi Xu. Tianqi Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Tianqi, Jinliang Wang, Li Feng, et al.. (2025). Development of a novel nanobody-fused flagellin adjuvant to enhance immunogenicity in a PCV2 subunit vaccine. Microbial Pathogenesis. 207. 107912–107912.

Zhang, Jie, Tianqi Xu, Ayman Abouzayed, et al.. (2024). Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.. Journal of Controlled Release. 370. 468–478. 4 indexed citations

Oroujeni, Maryam, Tianqi Xu, Evgenii Plotnikov, et al.. (2023). Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3. Nuclear Medicine and Biology. 124-125. 108384–108384. 6 indexed citations

Xu, Tianqi, Alexey Schulga, Е. В. Коновалова, et al.. (2023). Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences. 24(3). 2838–2838. 3 indexed citations

Xu, Tianqi, et al.. (2023). Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab. Cancers. 15(9). 2409–2409. 13 indexed citations

Vorobyeva, Anzhelika, Sarah Lindbo, Tianqi Xu, et al.. (2023). Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker. Molecular Medicine Reports. 29(2).

Xu, Tianqi, Jie Zhang, М. В. Белоусов, et al.. (2023). Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. Journal of Controlled Release. 355. 515–527. 11 indexed citations

Xu, Tianqi, Jie Zhang, Maryam Oroujeni, et al.. (2022). Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. Pharmaceutics. 14(3). 522–522. 7 indexed citations

Xu, Tianqi, Anna Orlova, Maryam Oroujeni, et al.. (2022). Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics. 14(7). 1475–1475. 7 indexed citations

10.

Garousi, Javad, Tianqi Xu, Olga Vorontsova, et al.. (2022). Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics. 14(8). 1612–1612. 3 indexed citations

11.

Vorobyeva, Anzhelika, Anna Orlova, Mark Konijnenberg, et al.. (2022). Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics. 14(5). 1092–1092. 6 indexed citations

12.

Xu, Tianqi, Jie Zhang, Vladimir Tolmachev, et al.. (2021). Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics. 13(3). 430–430. 14 indexed citations

13.

Garousi, Javad, Tianqi Xu, Anzhelika Vorobyeva, et al.. (2021). Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 13(11). 1847–1847. 8 indexed citations

14.

Xu, Tianqi, Maryam Oroujeni, Jie Zhang, et al.. (2021). The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics. 13(11). 1974–1974. 11 indexed citations

15.

Xu, Tianqi, Anzhelika Vorobyeva, Alexey Schulga, et al.. (2021). Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. Cancers. 13(16). 3939–3939. 11 indexed citations

16.

Deyev, Sergey M., Tianqi Xu, Alexey Schulga, et al.. (2021). Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. Cancers. 13(14). 3589–3589. 12 indexed citations

17.

Vorobyeva, Anzhelika, Tianqi Xu, Anna Orlova, et al.. (2021). Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics. 13(6). 839–839. 11 indexed citations

18.

Xu, Tianqi, Anzhelika Vorobyeva, Maryam Oroujeni, et al.. (2020). Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers. 13(1). 85–85. 25 indexed citations

19.

Lindbo, Sarah, Hao Liu, Javad Garousi, et al.. (2020). HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. Pharmaceutics. 12(4). 391–391. 7 indexed citations

20.

Rinne, Sara S., Tianqi Xu, Stefan Ståhl, et al.. (2020). Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. International Journal of Molecular Sciences. 21(4). 1312–1312. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact